Centessa Pharmaceuticals plc (CNTA)

Centessa Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	6.85	-	-	-
Gross Profit	-	6.85	-	-	-
Selling, General & Admin	50.81	53.73	55.2	43.01	1.14
Research & Development	150.24	124.41	155.08	96.32	9.3
Operating Expenses	201.06	178.14	210.28	139.33	10.44
Operating Income	-201.06	-171.28	-210.28	-139.33	-10.44
Interest Expense	-10.09	-9.91	-7.28	-2.55	-0.38
Interest & Investment Income	14.02	10.48	0.24	-	-
Currency Exchange Gain (Loss)	-1.8	0.8	-2.8	-3.6	-
Other Non Operating Income (Expenses)	0.11	-0.33	-0.76	-0.77	0.16
EBT Excluding Unusual Items	-198.82	-170.24	-220.87	-146.25	-10.66
Other Unusual Items	-34.1	-5.9	3.92	-15.08	-
Pretax Income	-232.91	-176.14	-216.95	-381.79	-10.66
Income Tax Expense	2.84	-25.06	-0.75	0.11	-
Net Income	-235.76	-151.09	-216.21	-381.9	-10.66
Preferred Dividends & Other Adjustments	-	-	-	-0.83	-
Net Income to Common	-235.76	-151.09	-216.21	-381.07	-10.66
Shares Outstanding (Basic)	114	96	93	75	15
Shares Outstanding (Diluted)	114	96	93	75	15
Shares Change (YoY)	19.02%	2.97%	24.26%	401.11%	-
EPS (Basic)	-2.06	-1.57	-2.31	-5.07	-0.71
EPS (Diluted)	-2.06	-1.57	-2.31	-5.07	-0.71
Free Cash Flow	-142.09	-160.51	-201.68	-136.34	-10.63
Free Cash Flow Per Share	-1.24	-1.67	-2.16	-1.81	-0.71
Gross Margin	-	100.00%	-	-	-
Operating Margin	-	-2499.39%	-	-	-
Profit Margin	-	-2204.66%	-	-	-
Free Cash Flow Margin	-	-2342.20%	-	-	-
EBITDA	-200.71	-170.97	-210.15	-139.3	-10.43
D&A For EBITDA	0.34	0.31	0.13	0.03	0.01
EBIT	-201.06	-171.28	-210.28	-139.33	-10.44

Updated Mar 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q